Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin resistance atherosclerosis study

Stroke

Volumn 29, Issue 8, 1998, Pages 1498-1503

  Haffner, Steven M ^a,k   D'Agostino Jr , Ralph ^b   Mykkänen, Leena ^b   Hales, C N ^c   Savage, Peter J ^d   Bergman, Richard N ^e   O'Leary, Dan ^f   Rewers, Marian ^g   Selby, Joe ^h   Tracy, Russell ⁱ   Saad, Mohammed F ^j  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Department of Public Health Sciences ^*

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h DIVISION OF RESEARCH   (United States)

ⁱ UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

Atherosclerosis; Insulin; Plasminogen activator inhibitor 1; Proinsulin

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN;

ADULT; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031904101     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.8.1498     Document Type: Article

References (63)

1. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
2. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive during 9-1/2 year follow-up of the Helsinki Policeman Study population. Acta Med Scand. 1985;701(supp)):38-52.
3. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study 10 years later. Horm Metab Res. 1985;15(suppl):41-46.
4. Després JP, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
5. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype - a report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol. 1994;4:40-45.
6. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia. 1992;35:766-770.
7. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol. 1994;140:857-869.
8. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes W, Cram KB, Hutchinson RG, for Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66-73.
9. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercouri M, Uusitupa M. Carotid artery intima media thickness and its determinants in elderly patients with NIDDM and in non-diabetic subjects. Stroke. 1996; 27:1986-1992.
10. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Verme D. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes. 1996;45:736-741.
11. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
12. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YDI, Sands RE, Pei D, Savage PH, Bergman RN. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 1994;43: 1114-1121.
13. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-1076.
14. Agewall S, Fagerbern B, Attvall S, Wendelhog I, Urbanavjejus V, Wikstrand J. Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke. 1995;26:956-960.
15. Bressler P, Bailey S, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996;39:1345-1350.
16. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
17. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 1987;30:698-702.
18. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31: 355-360.
19. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN. Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1989;1:293-295.
20. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D Jr. Disproportionately elevated proinsulin in Pima Indians with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70:1247-1253.
21. Reaven GM, Chen Y-DI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993;76:44-48.
22. Birkeland KI, Torjesen PA, Erikson J, Vaaler S, Groop L. Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia. Diabetes Care. 1994;17:1307-1310.
23. Haffner SM, Bowsher RR, Mykkänen L, Hazuda HP, Mitchell BD, Valdez RA, Gingerich R, Monterossa A, Stern MP. Proinsulin and specific insulin concentrations in high and low risk populations for type II diabetes. Diabetes. 1994;43:1490-1493.
24. Davies MJ, Rayman G, Gray IP, Day JL, Hales CN. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med. 1993;10:313-320.
25. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS. The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin dependent) diabetic subjects. Diabetologia. 1990;33:532-537.
26. Haffner SM, Mykkänen L, Valdez RA, Stern MP, Holloway DL, Monterrosa A, Bowsher RR. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79:1806-1810.
27. Gray RP, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost. 1995;73:261-267.
28. Mohamed-Ali V, Could MM, Gillies S, Goubet S, Yudkin JS, Haines AP. Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role for insulin. Diabetologia. 1995;38:1110-1117.
29. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes. 1993;42:1297-1302.
30. Kahn SE, Leonetti D, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity: Clinical Research Center Study. J Clin Endocrinol Metab. 1995;80:1399-1406.
31. Båvenholm P, Proudler A, Tornvall P, Godsland I, Landou C, de Faire U, Hamsten A. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation. 1995;92:1422-1429.
32. Yudkin JS, Denver AE, Mohamed-Ali V, Ramaiya KL, Nagi DK, Goubet S, McLarty DG, Swai A. The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence: a study of two ethnic groups. Diabetes Care. 1997;20: 1093-1100.
33. Wagenkneckt LE, Mayer EJ, Rewers M, Haffner SM, Selby J, Burke GM, Henkin L, Howard G, Savage PJ, Saad MF, Bergman RN, Hamman R. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design, and recruitment results. Ann Epidemiol. 1995;5:464-471.
34. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
35. Wong M, Edelstein J, Wollman J, Bond G. Ultrasonic-pathological comparison of the human arterial wall: verification of intima-media thickness. Arteriosder Thromb. 1993;13:482-486.
36. Bond MG, Barnes RW, Riley WA, Wilmoth SK, Chambless LE, Howard G, Owens B. for ARIC Study Group. High resolution B-mode ultrasound scanning methods in communities study (ARIC). J Neuroimaging. 1991; 1:68-72.
37. Mercuri M, Bond MG, Nichols FT, Carr AA, Flack JM, Byington R. Raines J, for MIDAS Group. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intimal media thickness: the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). J Cardiovasc Diagn Proc. 1993;11:241-252.
38. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ. Sex differences in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1984;120:834-851.
39. Hamman RF, Marshall JA, Baxter J, Kahn LB, Mayer EJ, Orleans M, Murphy JR, Lezotte DC. Methods and prevalence of non-insulin dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Diabetes Study. Am J Epidemiol. 1989;129:295-311.
40. Haffner SM, D'Agostino R Jr, Saad MF, Rewers M, Mykkänen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenkneckt L, Bergman RN. Increased insulin resistance and insulin secretion in non-diabetic African Americans and Hispanics compared to non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-748.
41. Haffner SM, Howard G, Mayer E, Bergman RN, Savage P, Rewers M, Mykkänen L, Selby JV, Saad MF. Insulin sensitivity and acute insulin response in African Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997; 46:63-69.
42. World Health Organization. Diabetes Mellitus Report of a WHO Study Group. Technical Report Series No. 727. Geneva, Switzerland: World Health Organization; 1985.
43. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
44. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsibility from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
45. Herbert V, Lau K, Gottlieb C, Bleicher S. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965;25:1375-1384.
46. Sobey WJ, Beer SF, Carrington CA, Clark PM, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J. 1989;260: 535-541.
47. Ostrega D, Polonsky K, Nagi D, Yudkin J, Cox LJ, Clark PMS, Hales CN. Measurement of proinsulin and intermediates: validation of immunoassay methods by high-performance liquid chromatography. Diabetes. 1995;44:437-440.
48. Geffken D, Keating F, Kennedy M, Cornell E, Bovill E, Tracy R. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med. 1994;118: 1106-1109.
49. Clauss A. Gerinnungs physiologische Schnell methode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
50. Macy E, Meilahn E, Declerck P, Tracy R. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med. 1993;117:67-70.
51. Declerck P, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl. 1990;10:3-9.
52. Zwiebel WJ, Zagzebski JA, Crummy AB, Hirscher M. Correlation of peak Doppler frequency with lumen narrowing in carotid stenosis. Stroke. 1982;13:386-391.
53. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C, for ARIC Investigators. Carotid atherosclerosis measured by B-mode ultrasound in populations: association with cardiovascular risk factors in the ARIC study. Am J Epidemiol. 1991;134:250-256.
54. O'Leary DH, Polak JF, Wolfson SK, Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
55. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995; 91:764-770.
56. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89: 321-330.
57. Gray RP, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost. 1995;73:261-267.
58. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost. 1989;61:370-373.
59. Yudkin JS. Circulating proinsulin-like molecules. J Diabetes Complications. 1993;7:113-123.
60. Alessi MG, Peirreti F, Morange P, Henry M, Nalbone G. Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860-867.
61. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95-108.
62. Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MIJ. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM: ten-year follow-up from the diagnosis. Diabetes. 1996;45: 308-315.
63. Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Haffner SM, Miettinen HJJ, Uusitupa MIJ. Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction? Power spectral analysis in patients with non-insulin-dependent diabetes and non-diabetic subjects. Circulation. 1997;96:1185-1191.